175 related articles for article (PubMed ID: 29433584)
1. Ipilimumab induced digital vasculitis.
Padda A; Schiopu E; Sovich J; Ma V; Alva A; Fecher L
J Immunother Cancer; 2018 Feb; 6(1):12. PubMed ID: 29433584
[TBL] [Abstract][Full Text] [Related]
2. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
Garcia CA; El-Ali A; Rath TJ; Contis LC; Gorantla V; Drappatz J; Davar D
J Immunother Cancer; 2018 Aug; 6(1):83. PubMed ID: 30170622
[TBL] [Abstract][Full Text] [Related]
3. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
4. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
5. Acute visual loss after ipilimumab treatment for metastatic melanoma.
Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
[TBL] [Abstract][Full Text] [Related]
6. Remote-onset alopecia areata attributed to ipilimumab.
Pearson DR; Lewis K; Alkousakis T
Cutis; 2019 Dec; 104(6):E25-E27. PubMed ID: 31939941
[TBL] [Abstract][Full Text] [Related]
7. A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma.
Sakaguchi C; Yano S; Ashida K; Wada N; Ohe K; Nagata H; Matsuda Y; Sakamoto S; Sakamoto R; Ohnaka K; Uchi H; Furue M; Nomura M; Ogawa Y
Am J Case Rep; 2019 Jan; 20():106-110. PubMed ID: 30679413
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
Alniemi DT; Fischer A; Greene LA; Pierson JC
Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.
Abdallah AO; Herlopian A; Ravilla R; Bansal M; Chandra-Reddy S; Mahmoud F; Ong S; Gokden M; Hutchins L
J Oncol Pharm Pract; 2016 Jun; 22(3):537-42. PubMed ID: 25712627
[TBL] [Abstract][Full Text] [Related]
11. [Digital ischaemia with fingertip ulcers during ipilimumab therapy].
Zenati N; Charles J; Templier I; Blaise S
Ann Dermatol Venereol; 2020 Mar; 147(3):212-216. PubMed ID: 31864764
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
[TBL] [Abstract][Full Text] [Related]
13. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
Alnabulsi R; Hussain A; DeAngelis D
Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
15. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
16. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
de Moel EC; Rozeman EA; Kapiteijn EH; Verdegaal EME; Grummels A; Bakker JA; Huizinga TWJ; Haanen JB; Toes REM; van der Woude D
Cancer Immunol Res; 2019 Jan; 7(1):6-11. PubMed ID: 30425107
[TBL] [Abstract][Full Text] [Related]
18. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
Adler NR; Murray WK; Brady B; McCormack C; Pan Y
Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
[No Abstract] [Full Text] [Related]
19. Diet-dependent toxicity of ipilimumab in metastatic melanoma.
Majenka P; Hoffmann M; Rötzer I; Dimitrakopoulou-Strauss A; Koschny R; Longerich T; Enk A; Hassel JC
Eur J Cancer; 2019 Jan; 106():220-224. PubMed ID: 30528806
[No Abstract] [Full Text] [Related]
20. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
Tetzlaff MT; Nelson KC; Diab A; Staerkel GA; Nagarajan P; Torres-Cabala CA; Chasen BA; Wargo JA; Prieto VG; Amaria RN; Curry JL
J Immunother Cancer; 2018 Feb; 6(1):14. PubMed ID: 29433571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
